ADAMTS12 and lung carcinoma: We additionally identified statistically significant mutations in the metalloproteinases ADAMTS2 (15%) and ADAMTS12 (20%), and in GAS7 (12%) and NTM (10%) (Q < 0.01, Methods section, Fig. 1a, Supplementary Fig. 4c, Supplementary Data 6–7), which so far have not been reported as significantly mutated in any other lung cancer subtype.